-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, affected by policies such as volume procurement and medical insurance fee control, the in-hospital market has come under pressure, prescription drugs have gradually increased to OTC, and the terminal OTC market of retail pharmacies has become more and more hot
.
According to data from Minai.
com, there are 240 OTC drugs (by product name) that are expected to exceed 100 million yuan in terminal sales in physical pharmacies in Chinese cities in 2022, of which 109 maintain a positive growth trend
.
Ejiao continued to rank first with more than 4.
7 billion yuan, and tablets of Zixi and enteritis Ning exceeded 1 billion yuan
for the first time.
69 exclusive products are eye-catching, and Yunnan Baiyao and China Resources Pharmaceutical lead
in quantity.
The combined market is nearly 90 billion, and the best-selling products focus on two tens of billions of markets
According to the forecast data of Minai.
com, in 2022, there will be 240 OTC drugs with terminal sales of more than 100 million yuan in physical pharmacies in Chinese cities, with a total sales of more than 89 billion yuan, of which 94 are chemical drugs (including biological drugs) and 146 are proprietary Chinese medicines
.
Figure 1: Top 5 categories of chemical drugs (including biological drugs).
94 chemical drugs (including biological drugs) OTC drugs are distributed in 8 categories, among which the number of digestive system and metabolites is far ahead
.
Specifically, mineral supplements and vitamins accounted for 12 and 11 respectively, and consumers' health awareness is constantly strengthening
under the haze of the epidemic.
Figure 2: Top 5 categories of proprietary Chinese medicines
The 146 proprietary Chinese medicine OTC drugs were distributed in 13 categories, with the largest
number of drugs used for respiratory diseases.
Specifically, the number of three subcategories of cough and expectorant asthma medication, cold medicine, and heat and detoxification medicine was relatively average, 16, 14 and 12 respectively, and proprietary Chinese medicine for the treatment of common diseases was still recognized
by consumers 。
Blood tonic "medicine king" leads the high, 15 potential products achieve "three-year skyrocketing"
Table 1: OTC drugs with terminal sales of more than RMB800 million in physical pharmacies in Chinese cities in 2022
In 2022, it is expected that there will be 12 OTC drugs with terminal sales of more than 1 billion yuan in Chinese urban pharmacies, 3 chemical drugs and 9 proprietary Chinese medicines
.
From 2015 to 2022, the blood tonic drug ejiao has been ranked among the top 1 terminal products in China's urban physical pharmacies, and the peak sales of this product reached more than
6.
3 billion yuan in 2019.
In the past three years, leading enterprises have strengthened channel control, and the sales of this product have declined, but they still hold the championship
.
In 2022, the sales of this product is expected to be 4.
705 billion yuan, with Dongea Ejiao accounting for more than 2 billion yuan, and Shandong Fupai Ejiao also winning more than 1.
2 billion yuan
.
Figure 3: Sales of two new 1 billion OTC drugs (billion yuan)
Pian Zixi is an exclusive product of Zhangzhou Pian Zixi Pharmaceutical, and it is also the top 1 product of terminal liver disease drugs in China's urban physical pharmacies, and the sales of this product have soared in the past five years, and the sales are expected to exceed 1.
1 billion yuan
in 2022.
Enteritis Ning tablets is an exclusive product of Jiangxi Kang'en Bei Traditional Chinese Medicine, and it is also the top 1 intestinal drug product in China's urban physical pharmacy, with sales expected to exceed 1 billion yuan
for the first time in 2022.
Table 2: OTC drugs with a growth rate of more than 10% for three consecutive years
The growth rate of 15 OTC drugs in China's urban physical pharmacy terminals has been above 10% for three consecutive years, and the market potential cannot be underestimated
.
Chemical drugs accounted for 9, of which 3 were mineral supplements, in addition, proprietary Chinese medicines accounted for 6.
Huoxiang Zhengqi oral liquid is a top 1 product of heat repellent, in 2017 in China's urban physical pharmacy terminal sales exceeded 1 billion yuan, in 2019 the growth rate fell slightly by 4.
14%, 2020-2022 to maintain double-digit rapid growth, 2022 is expected to exceed 1.
8 billion yuan, if this trend continues, it is expected to exceed 2 billion yuan
in 2023.
At present, two companies have obtained production approvals for the product, and most of the market is controlled by Taiji Group Chongqing Fuling Pharmaceutical
.
The growth of the three mineral supplements is also very amazing, the sales of calcium carbonate D3 chewable tablets are 190 million yuan in 2019 and are expected to rise to 419 million yuan in 2022; the sales of calcium carbonate tablets are less than 100 million yuan in 2019 and are expected to reach 319 million yuan in 2022; the sales of compound calcium gluconate oral solution are 150 million yuan in 2019 and are expected to reach 315 million yuan
in 2022.
These three OTC drugs are mainly competed by domestic pharmaceutical companies, which shows that the trust of domestic brands of mineral supplements in consumer groups is rapidly increasing
.
The 69 exclusive OTC drugs are super eye-catching, and Yunnan Baiyao and China Resources Pharmaceutical lead in the number
Table 3: Companies with two or more exclusive OTC drugs
Yunnan Baiyao and China Resources Pharmaceutical both lead the way, each with 4 exclusive OTC drugs expected to exceed 100 million
yuan in sales in 2022.
The second echelon includes Sanjin Pharmaceutical, Taiji Group and Tasly, each with 3 OTC drugs with sales of more than 100 million
.
The third echelon includes GPH Group, Wyeth, Kangbei, Ma Yinglong Pharmaceutical Group, Johnson & Johnson and Beijing Tongrentang, each with 2 OTC drugs with sales of more than 100 million
.
In addition, each of the 40 companies has one OTC drug
with sales of more than 100 million.
Yunnan Baiyao's Yunnan Baiyao Band-Aid has always been the top 1 hemostatic drug product in the Chinese proprietary medicine market, with a market share of more than 80%.
Yunnan Baiyao aerosol ranks among the top 2 products for swelling and pain relief in the patent medicine market, and its market share is expected to rise to more than 9% in 2022; The sales of cold stop capsules in 2020 are less than 100 million yuan, and the growth rate in the past two years has reached double digits, and the sales are expected to exceed 130 million yuan in 2022, and the potential is expected
.
A number of exclusive OTC drugs of CR Pharma are ranked high in the market, and Zhengtian Pill ranks among the top 1 headache drugs (migraine) products in the patent medicine market, with a market share of more than 20%; Compound ejiao pulp and Sanjiu gastric granules are ranked among the top 2 products
for blood tonic medicine and gastric medicine (gastritis, ulcer) respectively.
Sanjin Pharmaceutical's Sanjin tablets are the top 1 products for urinary tract infections in the Chinese proprietary medicine market, with a market share of more than
30%.
Tai Chi Group's sinusitis oral liquid has grown by 12.
67% and 35.
20% in the past two years, and will top the top 1 rhinitis
drug products in the proprietary Chinese medicine market in 2022.
Tasly's nourishing serum brain particles are ranked among the top 2 products
of over-the-counter headache medicine (migraine).
Ma Yinglong Musk Hemorrhoid Cream of Ma Yinglong Pharmaceutical Group has always been the top 1 hemorrhoid drug product in the Chinese patent medicine market, with a market share of more than
20%.
The 100 billion OTC market continues to heat up, and 7 products have been "turned non-profit" since the beginning of this year
According to data from Minai.
com, in 2021, the total market size of terminal chemicals, biological drugs and proprietary Chinese medicines in China's urban physical pharmacies will be 267.
4 billion yuan, and OTC will account for 38.
9%, that is, more than 100 billion yuan
.
In recent years, more and more prescription drugs have been successfully converted to OTC, and the market size is expected to be further improved
.
Table 4: Drugs "disposed of" from 2022 to the present
Source: NMPA official website
According to the announcement statistics released by the NMPA official website, up to now, 7 products have been successfully converted to OTC this year, Pudi Blue Anti-inflammatory Tablets is expected to exceed 700 million yuan in China's urban physical pharmacy terminal sales in 2022, and Safflower Xiaoyao Tablets in Chinese urban public hospitals in 2021 The terminal sales of county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 200 million yuan, and the terminal sales of omeprazole enteric-coated tablets in China's public medical institutions exceeded 300 million yuan in 2020.
.
.
With the continuous advancement of medical improvement and the increasing pressure on the in-hospital market, pharmaceutical companies have turned their attention to retail pharmacy terminals, and "turning to non-government" has become an important strategic adjustment
.
In particular, some products already have a good consumption base in the prescription drug stage, and after switching to OTC, it will be more convenient for patients to purchase drugs, and the profits of enterprises will also be improved
。
In the long run, on the one hand, "disposing of non-insurance" can save national medical insurance funds and free up more space for innovative drugs to be "insured"; On the other hand, patients can purchase drugs in offline pharmacies and online e-commerce platforms without a doctor's prescription, which is beneficial to patients who need to purchase drugs for a long time; Third, the increase in drug purchase channels will also increase product sales and expand market share for enterprises; Fourth, for retail pharmacy terminals, increasing the category of OTC drugs can further enrich the types of drugs in the store and attract more patients to enter the door to consume
.
Source: Minainet database
Note: Minai.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; Minai.
com's "Drug Terminal Competition Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, and village clinics; All sales are based on the average retail price of the product
.
If there is any omission, welcome to correct!
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
